𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Southwest oncology group phase II study of arsenic trioxide in patients with refractory germ cell malignancies

✍ Scribed by Tomasz M. Beer; Catherine M. Tangen; Craig R. Nichols; Kim A. Margolin; Robert Dreicer; William T. Stephenson; David I. Quinn; Derek Raghavan; E. David Crawford

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
78 KB
Volume
106
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II study of arsenic trioxide and a
Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study
✍ JE Chang; PM Voorhees; JM Kolesar; HG Ahuja; FA Sanchez; GA Rodriguez; K Kim; J πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 115 KB

Arsenic trioxide (As 2 O 3 ) has established clinical activity in acute promyelocytic leukaemia and has pre-clinical data suggesting activity in lymphoid malignancies. Cell death from As 2 O 3 may be the result of oxidative stress. Agents which deplete intracellular glutathione, such as ascorbic aci

A Phase II trial of vinorelbine tartrate
A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy : A Southwest Oncology Group study
✍ Robert P. Whitehead; James Moon; S. Spence McCachren; Evan M. Hersh; Wolfram E. πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 84 KB πŸ‘ 3 views

## Abstract ## BACKGROUND Single‐agent chemotherapy with dacarbazine continues to be the standard of care for the treatment of metastatic melanoma. However, there is a large population of patients who have failed first‐line therapy and might benefit from additional treatment. In the current study,

A phase II trial of interferon-Ξ± and 5-f
A phase II trial of interferon-Ξ± and 5-fluorouracil in patients with advanced renal cell carcinoma: A Southwest Oncology Group study
✍ Laurence Elias; Brent A. Blumenstein; Julie Kish; Robert C. Flanigan; James L. W πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 355 KB πŸ‘ 1 views

## BACKGROUND. Renal cell carcinoma is a common neoplasm that is often refractory to treatment. It is occasionally responsive to immunoniodulating agents including interferon-a, which enhances the effects of 5-fluorouracil upon cells. Combinations of these two drugs have been most frequently tested